Le Lézard
Classified in: Health
Subjects: TDS, PET, FVT

Kindred Biosciences to Present at the Oppenheimer 28th Annual Healthcare Conference

SAN FRANCISCO, March 8, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Oppenheimer 28th Annual Healthcare Conference on March 20-21, 2018 in New York City.

Kindred Biosciences, Inc. Logo

Denise Bevers, Co-Founder and Chief Operating Officer, will present and be available for one-on-one meetings at which investors will have the opportunity to discuss key therapeutic programs in development and upcoming milestones.

Presentation Details:

Date: Wednesday, March 21, 2018

Time: 2:10 - 2:40 PM EDT (11:10 - 11:40 AM PDT)

Location: The Westin New York Grand Central, Track 61 room

Webcase URL:  https://www.veracast.com/webcasts/opco/healthcare2018/15212424202.cfm

An archived version of the webcast will be available for 30 days on the Company's website: http://kindredbio.com/investor-relations/events/.

About Kindred Biosciences

Kindred Biosciences is a pre-commercialization stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.

For more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

Russell Radefeld
(650) 701-7904


SOURCE Kindred Biosciences, Inc.

These press releases may also interest you

at 02:30
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed a digital pathology contract with Instituto Português de Oncologia de Lisboa (IPO Lisboa). IPO Lisboa is renowned for its cancer care and is the first hospital...

at 02:00
Based on its recent analysis of the global smart packaging technology market, Frost & Sullivan recognizes the Internet of Packaging platform by Water.io with the 2018 Global Entrepreneurial Company of the Year Award. Water.io's innovative...

at 02:00
CERRITOS, Calif., June 18, 2018 /PRNewswire-PRWeb/ -- InBody will offer body composition solutions to American Diabetes Association (ADA) 78th Scientific Sessions attendees, June 22 to June 25 in Orlando, FL. The medical device manufacturer will also...

at 01:00
Based on its recent analysis of the North American market for artificial intelligence (AI) for aging research and drug development, Frost & Sullivan recognizes Insilico Medicine with the 2018 North American Technology Innovation Award. The company's...

at 01:00
ALDERLEY EDGE, United Kingdom, June 19, 2018 /PRNewswire-PRWeb/ -- "Our team of research scientists and software engineers wanted to get scientists back to their research and enable smoother projects," says Paul Faulder, CEO, Elixir. "iTraX takes a...

at 00:49
Carmentix Pte. Ltd. is proud to announce a research collaboration with The University of Melbourne (UoM), The Chinese University Hong Kong (CUHK) and The Henan Province People's Hospital for a clinical Preterm Birth study to validate Carmentix's...

News published on 8 march 2018 at 16:01 and distributed by: